drugset
drugset / Trial / NCT06277011

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

NCT06277011 ↗

Phase 0 Unknown 18 enrolled Anhui Provincial Hospital Leman Biotech Co., Ltd. · collab
NaSequentialOpen-labelTreatment

Summary

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies

Timeline

Start
2023-02-10
Primary completion
2025-02-01
Completion
2025-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Metabolically Armed CD19 CAR-T cells Cell therapy — Intravenous

Indications

acute lymphoblastic leukemia